Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 4, 2015, Pages 508-515

  Pan, Xianying ^a   Simon, Teresa A ^a   Hamilton, Melissa ^a   Kuznik, Andreas ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

Atrial fibrillation; Hemorrhagic stroke; Ischemic stroke; Patient outcomes

Indexed keywords

ADOLESCENT; ADULT; AGED; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; COMPARATIVE STUDY; COMPLICATION; COST; ECONOMICS; EPIDEMIOLOGY; FACTUAL DATABASE; FEMALE; HOSPITAL DISCHARGE; HUMAN; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; STROKE; UNITED STATES; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; UNITED STATES;

EID: 84939959245     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1144-8     Document Type: Article

References (28)

1. Milliman Inc (2010) Non-valvular atrial fibrillation and anticoagulation therapy: an actuarial study of the Medicare population. http://publications.milliman.com/research/health-rr/pdfs/non-valvular-atrial-fibrillation.pdf. Accessed 31 January 2013
2. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ (2004) Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110:1042–1046
3. Colilla S, Crow A, Simon T, Singer DE, Petkun W, Liu X (2012) Projected estimates of prevalence and annual growth rate of atrial fibrillation in the United States from a dynamic age-period progression model. Circ Cardiovasc Qual Outcomes 5:A206
4. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA 285:2370–2375
5. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS (2006) Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114:119–125
6. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988
7. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB et al (2013) Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127:e6–e245
8. Miyasaka Y, Barnes ME, Bailey K, Cha SS, Gersh BJ, Seward JB, Tsang TS (2007) Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 49:986–992
9. Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457
10. Dulli DA, Stanko H, Levine RL (2003) Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 22:118–123
11. Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A et al (2010) Stroke associated with atrial fibrillation-incidence and early outcomes in the North Dublin Population Stroke Study. Cerebrovasc Dis 29:43–49
12. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D’Agostino RB (1996) Stroke severity in atrial fibrillation: the Framingham Study. Stroke 27:1760–1764
13. Mercaldi CJ, Siu K, Sander SD, Walker DR, Wu Y, Li Q, Wu N (2012) Long-term costs of ischemic stroke and major bleeding events among medicare patients with nonvalvular atrial fibrillation. Cardiol Res Pract 2012:645469. doi:10.1155/2012/645469
14. Amin AN, Jhaveri M, Lin J (2011) Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors. Adv Ther 28:907–926
15. Amin AN, Jhaveri M, Lin J (2012) Temporal pattern and costs of rehospitalization in atrial fibrillation/atrial flutter patients with one or more additional risk factors. J Med Econ 5:548–555
16. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD et al (2011) Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123:933–944
17. Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J (2012) Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trials. J Med Econ 15:776–785
18. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139
19. Centers for Medicare and Medicaid Services (2007) Medicare coverage of skilled nursing facility care. http://www.medicare.gov/Publications/Pubs/pdf/10153.pdf. Accessed 17 May 2013
20. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S et al (2011) Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:517–584
21. Cutler DM, Long G, Berndt ER, Royer J, Fournier AA, Sasser A, Cremieux P (2007) The value of antihypertensive drugs: a perspective on medical innovation. Health Aff 26:97–110
22. Grabowski DC, Lakdawalla DN, Goldman DP, Eber M, Liu LZ, Abdelgawad T, Kuznik A, Chernew ME, Philipson T (2012) The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff 31:2276–2285
23. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
24. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992
25. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867
26. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891
27. Cha YM, Redfield MM, Shen WK, Gersh BJ (2004) Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 109:2839–2843
28. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ (2003) oral relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:2920–2925